What was Raul R. Rodriguez’s RIGL share ownership after the reported transaction?

After the transaction, Raul R. Rodriguez directly owned 228,102 shares of Rigel Pharmaceuticals common stock. This figure reflects his remaining direct holdings following the 7,607-share tax-withholding disposition reported on the Form 4 filing.

Rigel CEO reports tax-withholding share disposition

Rigel Pharmaceuticals CEO Raul R. Rodriguez reported an automatic share disposition related to taxes.

Filing Impact

(High)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Rigel Pharmaceuticals CEO Raul R. Rodriguez reported an automatic share disposition related to taxes. On 02/10/2026, 7,607 shares of common stock were withheld at $34.62 per share in a transaction coded “F,” which indicates payment of tax liability by delivering securities.

After this tax-withholding disposition, Rodriguez directly owned 228,102 shares of Rigel Pharmaceuticals common stock. This filing reflects an administrative equity and tax event rather than an open-market purchase or sale.

Insider Trade Summary

Exercise Price or Tax Liability: 7,607 shares

Exercise Price or Tax Liability 1 txn

Insider RODRIGUEZ RAUL R

Role CEO, President

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	7,607	$34.62	$263K

Holdings After Transaction: Common Stock — 228,102 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RIGL CEO Raul R. Rodriguez report on this Form 4?

Raul R. Rodriguez reported a tax-related share disposition. On February 10, 2026, 7,607 shares of Rigel Pharmaceuticals common stock were withheld in a code “F” transaction to satisfy tax obligations, rather than being sold on the open market.

How many RIGL shares were involved in Raul R. Rodriguez’s February 10, 2026 transaction?

The transaction involved 7,607 shares of common stock. These shares were used to cover tax liabilities at $34.62 per share in a code “F” tax-withholding disposition, rather than a voluntary buy or sell order in the market.

What does transaction code “F” mean in the RIGL Form 4 filing?

Transaction code “F” indicates payment of exercise price or tax liability by delivering securities. In this case, 7,607 Rigel Pharmaceuticals shares were withheld at $34.62 per share to satisfy tax obligations, not sold as a discretionary market transaction.

Is Raul R. Rodriguez a director or officer of Rigel Pharmaceuticals (RIGL)?

Yes. Raul R. Rodriguez is both a director and an officer of Rigel Pharmaceuticals, serving as CEO and President. The Form 4 identifies his roles and reports his direct ownership and the February 10, 2026 tax-withholding share disposition.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/12/2026 - 04:50 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RODRIGUEZ RAUL R

(Last)

(First)

(Middle)

RIGEL PHARMACEUTICALS, INC.

611 GATEWAY BLVD, SUITE 900

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CEO, President

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/10/2026		F		7,607	D	$34.62	228,102	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

	/s/ Raymond Furey (Attorney-in-Fact)	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR